My interdisciplinary team designs and performs basic and translational research studies and human clinical trials, to elucidate potential therapeutic targets for cancer and infectious diseases. My laboratory philosophy towards research is “why, what if, and just try it.” With this mindset, my basic research projects explore interconnections between seemingly disparate diseases, proteomics, and glycomics. Laser capture microdissection, immunohistochemistry, and reverse phase protein arrays are core technologies that allow us to analyze specific cell populations within the complex tissue microenvironment for each patient. Using these technologies, we elucidate potential therapeutic targets for cancer and infectious diseases. Protein signaling pathways of interest are autophagy, hormone regulation, and endocannabinoid receptor interactions.
I direct our CAP/CLIA accredited clinical proteomics laboratory which facilitates clinical trials and collaborative projects with pharmaceutical/biotechnology companies. We develop and patent technologies to address critical health care needs in the areas of tissue preservation, mechanisms of development/treatment of pre-malignant lesions, and novel diagnostic methods.
■ PINC trial (Preventing Invasive breast Neoplasia with Chloroquine): Deciphering signaling pathways in early stage breast cancer that are modulated by chloroquine.
■ Developing immunological portraits of breast ductal carcinoma in situ (DCIS) for potential therapeutic interventions.
■ Identifying potential biomarkers of energy metabolism of breast cancer cells.
■ Creating novel diagnostic technologies to decipher glycoprotein interactions.
■ A. J. VanMeter et al., Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics. 7(10), 1902-24 (2008).
IABR | 10920 George Mason Circle, Manassas, VA 20110